Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
MEI Pharma, Inc. - Common Stock
(NQ:
MEIP
)
3.070
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Sep 10, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about MEI Pharma, Inc. - Common Stock
< Previous
1
2
3
4
Next >
MEI Pharma to Report 2023 Fiscal Year End Financial Results and Provide Corporate Overview on September 26, 2023
September 21, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Confirms Receipt of Director Nominations From Anson and Cable Car
September 18, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal Cancer
August 16, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Results of Special Meeting of Stockholders
July 23, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction
July 19, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Responds to Anson and Cable Car
July 18, 2023
From
MEI Pharma, Inc.
Via
Business Wire
Anson and Cable Car File Preliminary Consent Materials to Remove Entire Board of Directors at MEI Pharma, Inc.
July 17, 2023
From
Anson Funds Management LP
Via
GlobeNewswire
MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction
July 17, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Postpones Special Meeting of Shareholders
July 13, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals
July 11, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals
July 07, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote “FOR” Pending Transaction with Infinity Pharmaceuticals
July 05, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals
June 29, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Responds to Anson and Cable Car
June 27, 2023
From
MEI Pharma, Inc.
Via
Business Wire
Anson Funds and Cable Car Capital Issue Statement Regarding the Inferior Proposed Transaction between MEI Pharma and Infinity Pharmaceuticals
June 27, 2023
From
Anson Funds Management LP
Via
GlobeNewswire
MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates
June 15, 2023
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor
June 13, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D. and Appointment of David M. Urso as Successor
June 02, 2023
From
MEI Pharma, Inc.
Via
Business Wire
Anson Funds and Cable Car Capital Issue Statement Regarding MEI Pharma’s Rejection of Their Acquisition Proposal
June 01, 2023
From
Anson Funds Management LP
Via
GlobeNewswire
MEI Pharma Board of Directors Rejects Unsolicited Proposal
June 01, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Confirms Receipt of Unsolicited Acquisition Proposal
May 30, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies
May 23, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Reports Third Quarter Fiscal Year 2023 Results and Operational Highlights
May 11, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces 1-for-20 Reverse Stock Split
April 14, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEIP STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of MEI Pharma, Inc. Is Fair to Shareholders
February 23, 2023
From
Halper Sadeh LLC
Via
Business Wire
MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates
February 23, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Reports Second Quarter Fiscal Year 2023 Results and Operational Highlights
February 09, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Adjournment of Annual Meeting of Stockholders
December 06, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Initiates Strategic Realignment
December 05, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting
December 05, 2022
From
MEI Pharma, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today